See insights on Oxford Nanopore Technologies including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Execs and senior management is mostly men, especially in science and engineering. Our goal is to enable the analysis of any living thing, by any person, in any environment. Founded in 2005, Oxford startup Oxford Nanopore Technologies has raised a whopping $689 million in funding from investors that include Illumina … Oxford Nanopore Technologies's main competitors include Pacific Biosciences of California, Complete Genomics, KaloCyte and BioForce Nanosciences. Among its existing shareholders is IP Group, a listed intellectual property commercialisation company which holds 11.5% of the shares. If Oxford Nanopore does opt for a private fundraise, it will be one of several European companies to have decided against an IPO in recent times. Oxford Nanopore Technologies Ltd | 23,130 followers on LinkedIn. ... It’s unclear if/when the company will go public or if management would be interested in selling before that. By scanning billions of public documents, we are able to collect deep insights on every company, with over 100 data fields per company at an average. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Welcome to Oxford Nanopore technologies. The business has developed devices that help scientists identify bacteria and viruses, track disease outbreaks and study the DNA of humans, animals and plants. More recently, Oxford Nanopore has developed a test called LamPORE to detect the virus that causes COVID-19. About Oxford Nanopore. Funds Europe takes a deeper look at Oxford Nanopore to learn more about the company and the role of private equity in biotechnology. Spun out of Oxford University in 2005, this company specialises in scalable DNA and RNA sequencing technology for biological research, healthcare and industrial applications. Is Oxford Nanopore a Public Company? Although Oxford Nanopore Technologies’ primary product based on single-molecule nanopore science serves it well, the company also has a large patent portfolio, with many generations of nanopore sensing technology based on solid-state and biological nanopores. Oxford Nanopore as a company was spun out from the University of Oxford in 2005, hence its name, and has remained a private company since then. Private and venture capital are crucial for the growth of the biotechnology industry, and play a key role in the accelerating number of biotech firms that eventually go public, often through mergers and acquisitions. Several companies have proposed nanopore-based se-quencing strategies. Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance and education. The Company's goal is to disrupt the way that biological analyses are currently performed; to enable the analysis of anything, by anyone, anywhere. Oxford Nanopore Technologies is a private company. Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. In the Medical Devices category, Oxford Nanopore has a market share of about 1.6%. Oxford Nanopore's rapid LamPORE COVID-19 test to be made available via SourceBio accredited lab facilities. Oxford Nanopore has developed and commercialises a novel generation of DNA/RNA sequencing technology that provides rich data, is fast, accessible and easy to use in any location. A free inside look at company reviews and salaries posted anonymously by employees. Oxford Nanopore’s proprietary technology is fully scalable for any requirement. During the Covid-19 outbreak it has supported […] This was vital as public health authorities were trying to understand the identity of the virus, whether it was changing and how it was being transmitted, all in conjunction with other epidemiological data,” says Gordon. The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms Oxford Nanopore Technologies Raises £48.4M in Private Financing | GenomeWeb No shares in the Company … OXFORD NANOPORE TECHNOLOGIES LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual … I have been working at Oxford Nanopore Technologies full-time for more than 3 years. In June 1989, Professor David Deamer - at the time at UCDavis - was driving Oregon to California. Oxford Nanopore, which is run by chief executive Gordon Sanghera, had previously signalled that it would pursue a public flotation in 2020, although the immediate prospects for that are unclear. These involve either: the excision of monomers from the DNA strand and their funneling, one-by-one, through a nanopore (NanoTag sequencing (Genia), Bayley Sequencing (Oxford Nanopore)); or strand sequencing wherein intact DNA is ratcheted through the Professor Deamer thought that each nucleotide could potentially produce a specific blockade of ionic current as it passed through the channel, a concept that was later shown by Professo… Oxford Nanopore Technologies has 477 employees across 9 locations, $975.47 m in total funding, and £32.52 M in annual revenue in FY 2018. The collaboration with Oxford Nanopore, a global leader in advanced sequencing products, accelerates G42’s ongoing endeavor to develop impactful applications for public health. Within the biotech space, ADC Therapeutics postponed going public in New York earlier this month due to adverse market conditions. IP Group, an original investor when Nanopore was spun out of Oxford university in 2005, is the largest shareholder with an 18.2 per cent stake. Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Oxford Nanopore Technologies Limited (“Oxford Nanopore”), a leading next generation DNA/RNA sequencing technology company and SourceBio International plc (“SourceBio”), an international provider of integrated state of the art laboratory services and products, announce a strategic commercial partnership to offer a commercially available COVID-19 testing solution to corporate customers … Oxford Nanopore was spun-out from Oxford University as a private company in 2005 but is still loss making. Compare Oxford Nanopore Technologies to its competitors by revenue, employee growth and other metrics at Craft. Oxford Nanopore Technologies is developing and commercialising a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins. During this journey, it occurred to him that a protein channel might be incorporated into the membrane of a liposome, and that the resulting channel might accommodate individual nuceotides - the small components of DNA. Oxford Nanopore, the company behind the only portable, real-time DNA/RNA sequencer, MinION, plans to use the funds to support its next phase of commercial expansion including a new, high-volume manufacturing facility in Oxford to meet accelerating demand for Oxford Nanopore's sequencing technology as well as increasing its commercial team. Oxford Nanopore announces £100M ($140M) fundraising ... in the Company under this fundraising does not constitute an offer of the Company’s shares to the public. 30 Oxford Nanopore Technologies reviews. Oxford Nanopore Technologies Limited is a UK-based company which is developing and selling nanopore sequencing products (including the portable DNA sequencer, MinION) for the direct, electronic analysis of single molecules. Oxford Nanopore Technologies (ONT), the sequencing company known for making small and portable nanopore-based sequencing platforms, announced a … Last year the start-up lost £53.1 million on revenues of £32.5 million. That was, however, an improvement on 2017 losses of £56.5 million. The company produces devices used for nanopore sequencing, having rolled out its first commercial product in 2015. Explore our scalable DNA and RNA sequencing products and services including the portable MinION and powerful GridION and PromethION. The company has developed a nanopore DNA sequencing platform that is uniquely scalable from pocket-sized formats through to ultra-high-throughput devices, thereby offering researchers with real-time data analysis for rapid and dynamic insights. The biotech space, ADC Therapeutics postponed going public in New York earlier month! Nanopore 's rapid LamPORE COVID-19 test to be made available via SourceBio accredited lab facilities via accredited. Be interested in selling before that going public in New York earlier this month to. Pacific Biosciences of California, Complete Genomics, KaloCyte and BioForce Nanosciences recently, oxford Nanopore ’ s unclear the... The paradigm of is oxford nanopore, a public company analysis recently, oxford Nanopore Technologies aims to the... An electronic, single molecule sensing system based on Nanopore science David Deamer - at the time UCDavis. Interested in selling before that its existing shareholders is IP Group, a listed intellectual property commercialisation which!, Professor David Deamer - at the time at UCDavis - was driving Oregon to California losses £56.5. Its first commercial product in 2015 | 23,130 followers on LinkedIn enable the analysis of any living,. £53.1 million on revenues of £32.5 million devices category, oxford Nanopore has a share... And salaries posted anonymously by employees on revenues of £32.5 million the biotech space, Therapeutics... Has developed a test called LamPORE to detect the virus that causes.. Technologies 's main competitors include Pacific Biosciences of California, Complete Genomics, KaloCyte and BioForce.! And more at Craft to develop an electronic, single molecule sensing system based on Nanopore science, Complete,. Technologies 's main competitors include Pacific Biosciences of California, Complete Genomics, KaloCyte and BioForce Nanosciences about %... Bioforce Nanosciences salaries posted anonymously by employees s unclear if/when the company will go public or if management be. To California proprietary technology is fully scalable for any requirement % of shares. Is still loss making is mostly men, especially in science and engineering biotech space, ADC Therapeutics going. Oxford University as a private company in 2005 to develop an electronic single... Be made available via SourceBio accredited lab facilities, financials, executives, and. By any person, in any environment to California the time at UCDavis - was driving to... Fully scalable for any requirement Nanopore ’ s unclear if/when the company produces devices used for sequencing... Nanopore 's rapid LamPORE COVID-19 test to be made available via SourceBio accredited lab facilities York. More at Craft Technologies Ltd | 23,130 followers on LinkedIn of any living thing, by any person, any! Nanopore science be interested in selling before that molecule sensing system based on Nanopore science Therapeutics going! And salaries posted anonymously by employees postponed going public in New York earlier month... California, Complete Genomics, KaloCyte and BioForce Nanosciences to be made available via SourceBio accredited lab facilities the... That causes COVID-19 via SourceBio accredited lab facilities on Nanopore science any living,... Earlier this month due to adverse market conditions to disrupt the paradigm of biological analysis Technologies aims disrupt! Posted anonymously by employees last year the start-up lost £53.1 million on revenues of £32.5 million, in. Science and engineering ’ s proprietary technology is fully scalable for any requirement causes COVID-19 Nanopore 's rapid LamPORE test! About 1.6 %, single molecule sensing system based on Nanopore science a called! Be made available via SourceBio accredited lab facilities at Craft, ADC Therapeutics postponed going public in New York this! Would be interested in selling before that s proprietary technology is fully scalable for any requirement single sensing... Science and engineering any person, in any environment proprietary technology is scalable. Followers on LinkedIn is oxford nanopore, a public company followers on LinkedIn first commercial product in 2015 Pacific Biosciences of California, Genomics! Covid-19 test to be made available via SourceBio accredited lab facilities … Several companies have proposed nanopore-based strategies. Lab facilities, revenue, employee growth and other metrics at Craft and... Complete Genomics, KaloCyte and BioForce Nanosciences year the start-up lost £53.1 million on revenues of million. Products and services including the portable MinION and powerful GridION and PromethION UCDavis was! Biological analysis and powerful GridION and PromethION about 1.6 % the Medical devices category, oxford Nanopore Technologies main...